Paper32197856
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
Rittberg R and 5 others. Clin Lung Cancer, 2020. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes. Papers, record 32197856. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32197856
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Hospitalization | Major topic |
| Lung Neoplasms | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Aged | |
| Carboplatin | |
| Etoposide | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Prognosis | |
| Retrospective Studies | |
| Survival Rate |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42505190 | Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42505190 | PubMed |
| 42258320 | Cancer Chemoimmunotherapy: Time Will Tell. | Cancer Immunol Res | 2026 | https://conductscience.org/library/papers/42258320 | PubMed |
| 40702109 | Spatial transcriptomics reveals macrophage domestication by epithelial cells promotes immunotherapy resistance in small cell lung cancer. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/40702109 | PubMed |
| 40618113 | The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report. | J Cardiothorac Surg | 2025 | https://conductscience.org/library/papers/40618113 | PubMed |
| 40529760 | A SEER prognostic nomogram analysis for extensive-stage small cell lung cancer: comparing the immune checkpoint inhibitors (ICIs) and non-ICIs eras. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40529760 | PubMed |
| 38487532 | The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report. | Front Immunol | 2024 | https://conductscience.org/library/papers/38487532 | PubMed |
| 38125937 | Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada. | Front Oncol | 2023 | https://conductscience.org/library/papers/38125937 | PubMed |
| 37795434 | Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study. | Front Oncol | 2023 | https://conductscience.org/library/papers/37795434 | PubMed |
| 36547179 | Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. | Curr Oncol | 2022 | https://conductscience.org/library/papers/36547179 | PubMed |
| 36532013 | Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review. | Front Immunol | 2022 | https://conductscience.org/library/papers/36532013 | PubMed |
| 36185266 | Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/36185266 | PubMed |
| 35454916 | Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35454916 | PubMed |
| 34436036 | Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada. | Curr Oncol | 2021 | https://conductscience.org/library/papers/34436036 | PubMed |
| 34295688 | First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. | Transl Lung Cancer Res | 2021 | https://conductscience.org/library/papers/34295688 | PubMed |
| 34046100 | Quality of Life and Psychological Distress of Lung Cancer Patients Undergoing Chemotherapy. | World J Oncol | 2021 | https://conductscience.org/library/papers/34046100 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32197856
GET https://conductscience.org/api/papers/v1/32197856/authors